Cisplatin-induced activation of TGF-β signaling contributes to drug resistance
Authors:
Open Access
- 1 January 2024
- journal article
- research article
- Published by Tech Science Press in Oncology Research
- Vol. 32 (1) , 139-150
Abstract
Growing evidence suggests an association between epithelial-mesenchymal transition (EMT), a hallmark of tumor malignancy, and chemoresistance to a number of anti-cancer drugs. However, the mechanism of EMT induction in the process of acquiring anti-cancer drug resistance remains unclear. To address this issue, we obtained a number of cisplatin-resistant clones from LoVo cells and found that almost all of them lost cell-cell contacts. In these clones, the epithelial marker E-cadherin was downregulated, whereas the mesenchymal marker N-cadherin was upregulated. Moreover, the expression of EMT-related transcription factors, including Slug, was elevated. On the other hand, the upregulation of other mesenchymal marker Vimentin was weak, suggesting that the mesenchymal-like phenotypic changes occurred in these cisplatin-resistant clones. These mesenchymal-like features of cisplatin-resistant clones were partially reversed to parental epithelial-like features by treatment with transforming growth factor-β (TGF-β) receptor kinase inhibitors, indicating that TGF-β signaling is involved in cisplatin-induced the mesenchymal-like phenotypic changes. Moreover, cisplatin was observed to enhance the secretion of TGF-β into the culture media without influencing TGF-β gene transcription. These results suggest that cisplatin may induce the mesenchymal-like phenotypic changes by enhancing TGF-β secretion, ultimately resulting in drug resistance.Keywords
This publication has 39 references indexed in Scilit:
- Influence of stress on extracellular matrix and integrin biologyOncogene, 2011
- The dynamic roles of TGF‐β in cancerThe Journal of Pathology, 2010
- Epithelial to Mesenchymal Transition Is Impaired in Colon Cancer Cells With Microsatellite InstabilityGastroenterology, 2010
- Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput ScreeningCell, 2009
- EMT, the cytoskeleton, and cancer cell invasionCancer and Metastasis Reviews, 2009
- Perturbation of transforming growth factor (TGF)-ß1 association with latent TGF-β binding protein yields inflammation and tumorsProceedings of the National Academy of Sciences, 2008
- Inducible FGFR-1 Activation Leads to Irreversible Prostate Adenocarcinoma and an Epithelial-to-Mesenchymal TransitionCancer Cell, 2007
- Epidermal Growth Factor Receptor Cooperates with Signal Transducer and Activator of Transcription 3 to Induce Epithelial-Mesenchymal Transition in Cancer Cells via Up-regulation of TWIST Gene ExpressionCancer Research, 2007
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002
- Colon Cancer Cells That Are Not Growth Inhibited by TGF-β Lack Functional Type I and Type II TGF-β ReceptorsAnnals of Surgery, 1995